Northern California Business Development Director Daniels HealthNorthern California Business Development DirectorSan Jose, CA$90,077–$130,174 / yearThe compensation offered will take into account internal equity and may vary depending on the candidate's geographic region, job-related knowledge, skills, and experience among other factors. Through cutting-edge innovation, infection control expertise, and a fierce commitment to sustainability, we're redefining what it means to protect frontline workers and the environment.
Director, Portfolio Omnichannel (Lung Hcp) Revolution Medicines, Inc.Director, Portfolio Omnichannel (Lung Hcp)Redwood City, CA$211,000–$264,000 / yearThe Director, Portfolio Omnichannel Strategy & Operations (Oncology Lung HCP) is a highly collaborative leader focused on both strategy & execution and is responsible for partnering with Brand & Commercial function Leads in translating oncology brand strategies into high-impact, compliant, and innovative customer engagement experiences. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Statistical Programming Revolution Medicines, Inc.Associate Director, Statistical ProgrammingRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: Position requires 14+ years of Statistical Programming experience with exploratory-stage oncology clinical trials, providing programming support and oversight of one or more clinical programs (early or late phase) within Statistical Programming function.
Associate Director, Environmental Health And Safety Revolution Medicines, Inc.Associate Director, Environmental Health And SafetyRedwood City, CA$186,000–$233,000 / yearManage occupational health program activities in partnership with internal stakeholders and external providers, including workplace injury and illness investigation and tracking, animal allergen questionnaire administration and follow-up, hepatitis B vaccination program support, ergonomics program coordination and continuous improvement, and maintenance of related documentation, metrics, and compliance records. Support Facilities Safety Programs through cross-functional collaboration and subject matter expertise, ensuring effective implementation of programs such as electrical safety, lockout/tagout, fall protection, confined space, heat illness prevention, and hot work, while maintaining clear role distinction from program ownership.
Senior Director, Compliance Training Revolution Medicines, Inc.Senior Director, Compliance TrainingRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner closely with Learning & Development, Corporate Communications, Legal, HR, regional compliance staff (U.S., Europe, and Asia), and business stakeholders to ensure effective deployment, localization, communication, and reinforcement of training programs.
Associate Director, Biostatistics Clinical Late Stage Revolution Medicines, Inc.Associate Director, Biostatistics Clinical Late StageRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Executive Director, Computational Systems Biology Revolution Medicines, Inc.Executive Director, Computational Systems BiologyRedwood City, CA$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Senior Director, Head Of Transactions & Partnering Revolution Medicines, Inc.Senior Director, Head Of Transactions & PartneringRedwood City, CARemote$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role partners closely with Business Development leadership and cross-functional stakeholders across Research, Development, Commercial, Finance, Legal, Intellectual Property, and Executive Management to advance high-priority opportunities from initial assessment through successful execution.
Director, Clinical Data Management Revolution Medicines, Inc.Director, Clinical Data ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Business Operations Revolution Medicines, Inc.Associate Director, Business OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role is ideal for a Associate Director -level professional who thrives on execution, can drive several projects in parallel, can navigate a matrix environment, and brings strong project leadership, communication and change management experience.
Director, Software Engineering - Common Platform Services Zscaler, Inc.Director, Software Engineering - Common Platform ServicesSan Jose, CA$248,000–$310,000 / yearThe range displayed on each job posting reflects the minimum and maximum target for new hire salaries for the position across all US locations and could be higher or lower based on a multitude of factors, including job-related skills, experience, and relevant education or training. Zscaler is committed to providing reasonable support (called accommodations or adjustments) in our recruiting processes for candidates who are differently abled, have long term conditions, mental health conditions or sincerely held religious beliefs, or who are neurodivergent or require pregnancy-related support.
Senior Director, Executive & Enterprise Communications Revolution Medicines, Inc.Senior Director, Executive & Enterprise CommunicationsRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Senior Director, Executive & Enterprise Communications will serve as a trusted communications advisor to the CEO and select senior leaders while leading enterprise internal communications across a growing global organization.
Director, Molecular Pathology, Translational Sciences, Translational Research. Revolution Medicines, Inc.Director, Molecular Pathology, Translational Sciences, Translational Research.Redwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will: Biomarker Strategy: Define and execute molecular and digital pathology-driven biomarker strategies.
Associate Director, Global Healthcare Compliance Operations Revolution Medicines, Inc.Associate Director, Global Healthcare Compliance OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Lead implementation, enhancement, validation, and lifecycle management of systems supporting HCP/HCO engagements, advisory boards, speaker programs, grants and sponsorships, third-party due diligence, transparency reporting, monitoring and auditing activities, compliance training and certifications.
Senior Medical Director - Late Stage Revolution Medicines, Inc.Senior Medical Director - Late StageRedwood City, CA$346,000–$397,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Senior Director, Head Of Search & Evaluation Revolution Medicines, Inc.Senior Director, Head Of Search & EvaluationRedwood City, CARemote$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Working in close partnership with leaders across Research, Development, Commercial, Corporate Strategy, Portfolio Management, and Executive Management, this individual will lead the company's search and evaluation activities across discovery and clinical-stage opportunities.
Executive Director, Clinical Supply Chain Revolution Medicines, Inc.Executive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Associate Director, Global Omnichannel Solutions Delivery Revolution Medicines, Inc.Associate Director, Global Omnichannel Solutions DeliveryRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The individual will play a critical role in supporting global expansion by establishing scalable solutions, enabling adoption of global platforms, and ensuring new capabilities, brands, and regions can be added efficiently without rework or fragmentation.
Director, Regulatory Affairs (US Filing Lead) Revolution Medicines, Inc.Director, Regulatory Affairs (US Filing Lead)Redwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Required Skills, Experience and Education: Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Associate Director, Global Field Solutions Revolution Medicines, Inc.Associate Director, Global Field SolutionsRedwood City, CA$186,000–$233,000 / yearThe Opportunity: Revolution Medicines Information Sciences and Digital Innovation (ISDI) team is seeking an Associate Director, Global Field Solutions to lead the successful implementation of Commercial and Medical Go-To-Market technology solutions for field teams across new global regions, with an initial focus on Europe and Japan/Asia-Pacific. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Senior Director, Global Patient Safety Surveillance Revolution Medicines, Inc.Senior Director, Global Patient Safety SurveillanceRedwood City, CA$244,000–$305,000 / yearProvide relevant subject matter expertise for the design, development, maintenance, and support of one or more core GPS processes (i.e. comparative benefit-risk, signal detection & management, risk management, aggregate reporting, etc.) in compliance with applicable Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GVP), Good Documentation Practices (GDocP), etc., in alignment with the company's mission and objectives. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Quality Assurance Revolution Medicines, Inc.Associate Director, Clinical Quality AssuranceRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Associate Director, Quality Validation Revolution Medicines, Inc.Associate Director, Quality ValidationRedwood City, CA$186,000–$233,000 / yearAs a key member of the Quality organization, the Associate Director, Quality Validation partners closely with cross-functional teams within Pharmaceutical Development & Manufacturing (PDM) and external partners to develop and maintain robust validation strategies, support commercial manufacturing and product disposition activities, drive continuous improvement, and ensure consistent execution of validation programs across the global external manufacturing network. The Opportunity: The Associate Director, Quality Validation is responsible for providing strategic quality leadership and oversight of validation programs supporting Drug Substance (DS), Drug Product Intermediate (DPI), Drug Product (DP), packaging, and distribution activities across the company's global network of CDMOs, packaging partners, and suppliers.
Associate Director, Revenue Accounting And Finance Revolution Medicines, Inc.Associate Director, Revenue Accounting And FinanceRedwood City, CA$186,000–$233,000 / yearPrepare and analyze monthly product revenue and gross-to-net close activities, including the calculation, recording, and monitoring of gross-to-net accruals and related reserve balances for prompt pay discounts, copay and patient assistance programs, returns, Medicaid, Medicare Part D, 340B, VA/DoD, and other forms of variable consideration. Manage the day-to-day partnership with the external government pricing consultant, including coordinating required data submissions, reviewing government pricing calculations and related outputs, and supporting accuracy and compliance across government channels, including Medicaid, Medicare Part D, 340B, and VA/FSS programs.
Director, Regulatory Affairs - US Filing Lead Revolution Medicines, Inc.Director, Regulatory Affairs - US Filing LeadRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Required Skills, Experience and Education: Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Partner Development Director EverlawPartner Development DirectorOakland, CA$206,000–$260,000 / yearThis role focuses on net-new partner creation and the early phase of partner success: finding the right partners, structuring the right deals, aligning cross-functional teams, and helping those partnerships produce their first meaningful wave of business. Identify, evaluate, and recruit high-potential strategic partners-including service providers, resellers, global advisories, and legal solutions partners-to unlock growth across new segments and geographies.
Director, Stability Management, Analytical Development And Quality Control Revolution Medicines, Inc.Director, Stability Management, Analytical Development And Quality ControlRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Collaborate cross-functionally with teams in drug substance, drug product, supply chain, quality, regulatory, sourcing and other related team to ensure alignment of stability design and achieve stability study objectives.
Senior Director, Clinical Biomarker Operations Revolution Medicines, Inc.Senior Director, Clinical Biomarker OperationsRedwood City, CA$244,000–$305,000 / yearThe Opportunity: Revolution Medicines is seeking a strategic and experienced leader to serve as Senior Director, Clinical Biomarker Operations, responsible for leading the operational execution of biomarker and companion diagnostic (CDx) strategies across early- and late-stage clinical development programs. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Revolution Medicines, Inc.Executive Director, GCP QA (Good Clinical Practice, Quality Assurance)Redwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Director, IT Operations Form EnergyDirector, IT OperationsBerkeley, CAWhat you'll do: Own core IT infrastructure: servers, storage, virtualization, and cloud (Microsoft 365 / Azure and Google Workspace) - including tenant infrastructure, security baselines, licensing compliance, and endpoint integration - and the identity and access infrastructure (Entra ID / Active Directory, MFA, and conditional-access policies). Own the service desk, procurement, and IT asset/inventory management across all sites - through a Manager, IT Service & Procurement - defining SLAs and metrics and driving a strong customer-service culture for a multi-site, multi-shift user base.
Medical Director, Early-Stage Clinical Development Revolution Medicines, Inc.Medical Director, Early-Stage Clinical DevelopmentRedwood City, CA$295,000–$339,000 / yearHas demonstrated collaborative behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Data Management Revolution Medicines, Inc.Associate Director, Clinical Data ManagementRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Precision Medicine & Companion Diagnostics Revolution Medicines, Inc.Associate Director, Precision Medicine & Companion DiagnosticsRedwood City, CA$186,000–$233,000 / yearThe Opportunity: Revolution Medicines is offering a highly visible opportunity for talented and motivated individual to join our Precision Medicine Companion Diagnostics team as an Associate Director, Companion Diagnostics within the Translational Medicine function, which supports CDx development across RevMed portfolio. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Senior Director, Molecule Global Regulatory Lead Revolution Medicines, Inc.Senior Director, Molecule Global Regulatory LeadRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provide strategic oversight for the planning and execution of major regulatory submissions, including INDs, CTAs, amendments, expedited designation requests, marketing applications, and lifecycle submissions.
Senior Director, Clinical Data Management Revolution Medicines, Inc.Senior Director, Clinical Data ManagementRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Senior Director of Clinical Data Management provides high-level leadership for data management functions within clinical research, focusing on strategic development, operational execution, and regulatory compliance to ensure data integrity for clinical trials.
Associate Director, Clinical Operations Revolution Medicines, Inc.Associate Director, Clinical OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Proven experience working with investigators, external experts and regulatory agencies and oversight of Contract Research Organizations and third-party vendors including realigning with CRO partners when deliverables are at risk, negotiating solutions and leading After Action Reviews to share lessons learned.
Senior Director, Global Value Access And Pricing, Nsclc Revolution Medicines, Inc.Senior Director, Global Value Access And Pricing, NsclcRedwood City, CARemote$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As the Global Value & Access lead on Disease Area Strategy Teams and governance forums, the Senior Director influences clinical development, indication sequencing, lifecycle management, launch planning, and business development decisions to maximize long-term asset value and sustainable patient access.
Center Director At Math Learning Center MathnasiumCenter Director At Math Learning CenterSan Jose, CA$55,000–$75,000 / yearJob Responsibilities: As Center Director of Mathnasium of Berryessa, you will act as general manager of the center, including ownership of the following: Sales and marketing responsibilities, including promptly responding to leads and successfully enrolling students. All applicants will be required to take a math literacy test to demonstrate math proficiency, provide work authorization, and successfully complete a background check and Live Scan fingerprinting, in accordance with applicable California law.
Director Of Global AWS Cloud Alliance Zscaler, Inc.Director Of Global AWS Cloud AllianceSan Jose, CA$182,000–$260,000 / yearThe range displayed on each job posting reflects the minimum and maximum target for new hire salaries for the position across all US locations and could be higher or lower based on a multitude of factors, including job-related skills, experience, and relevant education or training. Zscaler is committed to providing reasonable support (called accommodations or adjustments) in our recruiting processes for candidates who are differently abled, have long term conditions, mental health conditions or sincerely held religious beliefs, or who are neurodivergent or require pregnancy-related support.
Director, Alliance Management Revolution Medicines, Inc.Director, Alliance ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
Executive Director, Global Patient Safety Quality And Compliance - Pharmacovigilance Revolution Medicines, Inc.Executive Director, Global Patient Safety Quality And Compliance - PharmacovigilanceRedwood City, CA$265,000–$331,000 / yearThe responsibilities of this role include oversight of the PV-QMS, PV training strategy, PV controlled documentation, inspection and audit management, ensuring inspection readiness, Corrective Action Preventive Action (CAPA) management, Quality Assurance (QA), and maintenance of Good Clinical Practice (GCP), and Good Pharmacovigilance Practices (GVP) in partnership with GPS management, QA, and staff. This critical role will require strategic thinking, expert knowledge of global PV regulations (i.e. GCP, GVP), the ability to influence and communicate ideas effectively, results orientation, collaboration with cross-functional teams, technical expertise, and vendor management skills to ensure compliance with regulatory requirements to safeguard patient well-being.
Director, Pipeline & Product Communications Revolution Medicines, Inc.Director, Pipeline & Product CommunicationsRedwood City, CA$211,000–$264,000 / yearReporting to the Senior Director, Pipeline & Product Communications, this role will partner closely with cross-functional teams, including R&D, Medical Affairs, Regulatory, Commercial, Market Access, Patient Advocacy, Legal, and Corporate Communications, to ensure clear, consistent, and differentiated communications for the assigned tumor area. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, US Medical Affairs Strategic Operations Revolution Medicines, Inc.Director, US Medical Affairs Strategic OperationsRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Led complex, cross-functional medical workstreams spanning launch readiness, scientific communications, congress strategy, HEOR/IEP coordination, and external engagement strategy for new product launches, indication expansions, and lifecycle management.
Executive Director, Early Clinical Development Revolution Medicines, Inc.Executive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Externally Sponsored Research Revolution Medicines, Inc.Director, Externally Sponsored ResearchRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Director, Externally Sponsored Research (ESR) (including investigator sponsored trials and collaborative research) will lead the strategy, oversight, and execution of Revolution Medicines' ESR processes within one of our disease areas.
Senior Director, Global CMC Lead Revolution Medicines, Inc.Senior Director, Global CMC LeadRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director, Global CMC Lead will provide cross-functional leadership and accountability for defining and executing integrated CMC strategies across development-stage and late-stage small molecule programs.
Senior Medical Director, Early-Stage Clinical Development Revolution Medicines, Inc.Senior Medical Director, Early-Stage Clinical DevelopmentRedwood City, CA$346,000–$397,000 / yearHas demonstrated collaborative behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Projects-North America NextpowerDirector, Projects-North AmericaFremont, CaliforniaAt Nextpower, we are leading in the energy transition, providing the most comprehensive portfolio of intelligent solar tracker and software solutions for solar power plants, as well as strategic services to capture the full value of solar power plants for our customers. At Nextpower, we are driving the global energy transition with an integrated clean energy technology platform that combines intelligent structural, electrical, and digital solutions for utility-scale power plants.
Deputy Chief Human Resources Officer / Human Resources Director – College of Nursing (hybrid) Samuel Merritt UniversityDeputy Chief Human Resources Officer / Human Resources Director – College of Nursing (hybrid)Oakland, CaliforniaIn this dual-capacity role, the individual serves as the dedicated HR Business Partner to the College of Nursing, providing strategic and operational leadership across talent strategy, workforce planning, employee relations, performance management, and organizational effectiveness for the University’s largest academic unit. Job Description Summary: The Deputy Chief Human Resources Officer / Human Resources Director – College of Nursing (hybrid) serves as the senior HR leader supporting the College of Nursing while also functioning as a key strategic partner to the Chief Human Resources Officer.
Project Director - Environmental Restoration Management CompanyProject Director - EnvironmentalHayward, CaliforniaPhysical Clearance: Successfully complete a pulmonary function test, including a respirator fit test, to ensure their ability to safely utilize the designated respirator selected for the role. Physical Activities: Ability to perform tasks that require, walking, bending, reaching, crouching, kneeling, climb, squat, crawl, lift above shoulder, reach, and twist.